Search Results

Just her, radioactive ligands, and steady hands. Every step felt like it could make or break the result, The pace and precision of GPCR research today — from high-throughput ligand screens to real-time signaling readouts — are built on the discipline Michelle’s path wasn’t linear. Her career didn’t follow a straight line — it zigzagged through long nights, and calculated leaps.

The Moment It Clicked Once the initial spark was lit, Michelle’s curiosity snowballed. For Early-Career Scientists: Your pivotal moment might not feel like fireworks. For innovators and biotech strategists, stories like Michelle’s reveal how scientific leadership emerges For GPCR research, leaders like Michelle are showing what happens when we follow the signal all the way . 🎧 Listen to the full conversation with Michelle Halls on  The Dr.

This lesson asks a deceptively simple question: What if our molecules—not our targets—are limiting discovery Lesson:  The structure-response relationship is rarely linear — and observing the unexpected is part This reroutes discovery toward: Functionally selective ligands Better therapeutic windows More predictable Advances in formulation and delivery have overcome earlier pharmacokinetic limitations. Terry Kenakin, monthly AMA discussions, and on-demand access to a library of expert GPCR teaching sessions

Learners can study at their own pace, shape the curriculum, and join live monthly AMA sessions with Dr Anyone who joins Premium before these changes go live will be grandfathered at their current rate , as Whether you’d like to partner, teach, share tools and technologies, or simply offer feedback , your input From free resources like the podcast and blog to our Premium ecosystem and Foundry initiatives, our mission Related Links 🔗 Explore Terry’s Pharmacology Corner → TerryKenakin.com 📧 Connect with us →   Hello@

(affinity, efficacy, co-operativity) Determining mechanisms of action for new GPCR ligands Elements and effective GPCR discovery Master advanced applications: Using new cellular assays to analyze GPCR ligand behavior Predicting activity and in vivo target coverage with real-time kinetics Discovering new ligands human G protein-coupled receptor biology and pharmacology Industry News Muscarinic drugs breathe new life into schizophrenia pipeline GPCR Dynamics Reveal Mechanisms for Drug Discovery DMS: Linking Protein

Raised in a small town in southern Sweden, he had never met anyone with a PhD and had little exposure foods, he saw life sciences as a field full of promise. Predictive GPCR-Ligand Modeling Carlsson's work quickly shifted from curiosity to impact. work inevitably reaches a point where novel, non-commercial ligands are needed. Looking for more insights like this? The Dr.

GPCR Premium: Sneak Peek Industry insights:  Confo VLAIO grant; Skye CB1 Ph2 miss; Chugai CT-388 in-license 🎥  Live AMA with Dr. Kenakin — October 30, 12 PM EST   Join Dr. Kenakin live and bring the questions that keep you thinking. Know the limits —where AI helps and where it still overpromises. Listen to the episode ➤ Why Dr.

De Graaf for their excellent work on Comparative Study of Allosteric GPCR Binding Sites and Their Ligandability Heterodimerization when Expressed Heterologously in Saccharomyces cerevisiae The beta 2 adrenergic receptor cross-linked signaling-competent receptors GPCRs in Neuroscience Astrocyte Gi-GPCR signaling corrects compulsive-like dendritic cells Methods & Updates in GPCR Research Generation of CRISPR/Cas9 modified human iPSC line Molecular Insights into GPCR Function Comparative Study of Allosteric GPCR Binding Sites and Their Ligandability

groundbreaking work on Positive allosteric modulation of a GPCR ternary complex Unlock Your Learning: Limited Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing UK announced the winners of its Transforming Cancer Therapeutics grant, which focuses on developing life-changing for schizophrenia Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing GPCR ternary complex GPCR Binders, Drugs, and more Progress on the development of Class A GPCR-biased ligands

They’re kinetic game-changers —compounds that rewrite the relationship between ligand , receptor , and pharmacologic terms. ✅ Foresight to exploit persistent binding  without triggering long-term toxic liabilities But it also means new liability surfaces : persistent effects can’t be simply “washed out” when things That’s the hidden liability beneath the kinetic edge. Irreversible binding isn’t a magic bullet. A growing on-demand library  where enzyme inhibition, activation, and metabolism are demystified with

eyJ1IjoiaHR0cHM6Ly9kb2kub3JnLzEwLjExMTEvYnBoLjcwMDcyIiwiciI6ImUyZGZlOTFjLTM5YzgtNDA5Yi04NTUyLWI5NjUwNGRlNzc4MyIsIm0iOiJtYWlsX2xwIiwiYyI6IjAwMDAwMDAwLTAwMDAtMDAwMC0wMDAwLTAwMDAwMDAwMDAwMCJ9 The B2D consortium revives biodiversity as a source for selective GPCR ligands

Maria Majellaro, highlighting their fluorescent ligand tools for live-cell GPCR assays.   industry side, Novo Nordisk, Septerna, and Deep Apple advance billion-dollar GPCR programs, while Eli Lilly GLP-1R/GIPR biased agonism enhances metabolic outcomes Ghrelin receptor flips D2 signaling without a ligand It emphasizes scaffold selection, linker optimization, and assay compatibility to enhance target binding Constitutive ghrelin receptor activity, not dimerization or ligand binding —reverses dopamine D2 signaling

Eric Trinquet, a veteran innovator behind functional GPCR assays like HTRF and IP-One, believes rigid and Tag-lite. Instead of chasing linear progress, Eric encourages young scientists to stay playful longer—embracing Dual control: not just brightness but fluorescence lifetime, with drastic shifts as pH drops. GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr.

Premium gives you the full context, links, and our editorial notes—this is just the teaser. Whether you’re designing a ligand, optimizing ADME, or predicting PK, enzyme inhibition defines what 🎥 Live AMA with Dr. Kenakin live. Each session shapes next month’s lessons—so your challenges guide the content. built for busy scientists A voice in future course topics Fresh, weekly content that stays relevant Live

Even the most elegant GPCR ligand can fail if it never reaches its receptor. The transition from “magic” to mechanistic understanding, championed by pioneers like A.J. 🎥  Coming Soon: Live AMA with Dr. Terry Kenakin This Month’s Live AMA — October 30 at 12 PM EST Join Dr. Kenakin live for an open Q&A session designed for discovery scientists.

This Week’s GPCR Intelligence: If you want cleaner decisions, start with the system—then the ligand. GPCR; a bidirectional GPCR switch modulates immune signaling; a machine-learning tool predicts GPCR–ligand Plus: new research on CaSR, leptin signaling, and inflammation-linked GPCRs — and curated roles in computational Premium delivers the full details, links, and expert commentary every week. Prediction, it turns out, is only powerful if you understand its limits. 🎧 Catch up while you wait:

Eric Trinquet shares what it really takes to bring a product to life—from sketch to shelf. But a pattern emerged: some scaffolds showed dual responsiveness to pH through lifetime and brightness And for those on the front lines of GPCR science, it’s a new lens to see what’s always been there—just 🎧 Listen to the full podcast episode here ⸻ More about Revvity pHSense Reagents GPCR Reagents Revvity GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr.

It’s about revealing therapeutic liabilities before  they derail development. Think of it this way: most receptors behave like switches—they stay off until flipped. But some leak current, like a switch glowing faintly in the dark. A growing on-demand library  of expert pharmacology lessons to revisit anytime. Pipeline efficiency isn’t luck—it’s literacy.

This week’s edition links ligand mechanism to the decisions that shape affinity, efficacy, selectivity Each week we highlight the decisions that move GPCR projects forward—from pharmacology essentials to ligand  Studies on active-state GPCR ensembles and their transducer coupling, biased angiotensin receptor ligands For GPCRs, fluorescent ligands have quietly become one of the most versatile technologies—supporting The Advantages Live-cell imaging:  visualize receptor–ligand interactions in real time, without disturbing

Depending on the type of GPCR, it can lead to different secondary messengers , like cAMP, IP3, which GPCR signaling: (A) an orthosteric ligand (orange) binds an inactive GPCR, the β2 adrenergic receptor Their physiological ligands are not fully understood, which opens new treatment possibilities. Some of the advantages of using fluorescent ligands for this are: Live-cell imaging:  receptor-ligand A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.

Developed to address long-standing challenges in GPCR internalization assays , pHSense™ reagents  combine live-cell developed to overcome three persistent barriers in internalization studies : Complex imaging workflows Limited addition to Revvity’s GPCR reagent portfolio , which supports every stage of the signaling cascade: GPCR ligand binding  – TR-FRET, radioligand, Tag-lite® G-protein activation  – cAMP, IP-One, GTP assays β-arrestin to the Podcast with Revvity’s Eric Trinquet → Explore the pHSense™ Reagent Line → Browse Revvity’s GPCR

honored to be chairing a session  in this track — with none other than Terry Kenakin  on the speaker lineup Hearing Terry speak is more than an academic experience — it’s like being handed a new set of tools to pharmacology series where Terry Kenakin breaks down receptor pharmacology, functional selectivity, and ligand scientists, biotech leaders, CRO professionals, and investors from around the globe meet Boston’s vibrant life GPCR ecosystem. 📅 September 24, 2025 📍 Pressed Café, Huntington Ave, Boston ⏰ 6–8 PM EST ⚠️ Space is limited

. 🚨 First-ever Live AMA with Dr. trafficking, and dynamics—if your probes preserve function, minimize phototoxicity, and work in both live This applied article walks through ligand-directed labeling, SNAP/Halo tags, and fluorescent ligands practical guidance on TR-FRET compatibility, photobleaching resistance, and 3D stack acquisition for tissue-like Physiological relevance:  Fluorescent ligands can retain receptor integrity—critical when signaling readouts

Without the right model, it’s like staring at identical twins—you can’t tell them apart until you see The shift continues linearly. Allosteric? The shift plateaus once the allosteric site saturates. You add a non-radioactive analog of a ligand, expecting it to displace binding. Without a framework, this looks like an assay error. a shift,” “seems like baseline activation”—you’re leaving risk on the table.

But for Ajay Yekkirala, that closed door lit the fuse for a career that would reimagine GPCR therapeutics His work spans deep academic research, startup life, and the application of machine learning and pharmacology that slow down or prevent good science from reaching patients — particularly in underfunded fields like of progress in structural biology and pharmacology, predicting how  a GPCR will respond to a given ligand In August 2025, Superluminal Medicines announced a collaboration with Eli Lilly and Company to advance

Terry's Corner – Curve Shifts Don’t Lie, But Your Eyes Might In early drug discovery, “those curves look practical framework to validate differences, confirm subtle shifts, and benchmark your results against literature Validate with confidence:  Benchmark your results against literature standards and confirm whether your Premium Members get a 50%+ discount when they join Terry’s Corner. 🚨 First-ever Live AMA with Dr. Listen to the whole conversation ➤ GPCR Happy Hour – Boston, September 2025 Space is limited.

Space is limited. Big ideas aren’t. The most valuable conversations don’t happen under fluorescent lights — they happen when the ties are Scientists, investors, and CRO professionals fly in from around the world, while Boston’s own vibrant life Axxam’s capabilities span the full spectrum of GPCR families, including aminergic, peptide, lipid, and on Huntington Ave in Boston 📅 Date:  September 24, 2025 ⏰ Time:  6-8 pm EST 👥 Capacity:  Space is limited

excelling in the PCAT and gaining admission to pharmacy school at the University of Michigan, it seemed like I realized in that moment that I didn't want to be a pharmacist but I had tailored four years of my life bulb moment where I felt for the first time in my life, I understood why people pursued a PhD. That project was her lightbulb moment. In life and career, taking risks can lead to personal and professional growth.

impair breathing, why xylazine complicates interventions, and how receptor-level insights can save lives Like many young scientists, she explored different paths and gained industry experience before realizing While writing a literature review on opioid and alcohol addiction susceptibility, something shifted. The work no longer felt like an assignment—it felt like a calling. “I really like academia.

Breakthroughs this week: Novo Nordisk cuts Ozempic® cost; Nxera launches obesity pipeline; Superluminal–Lilly Discover how factors like restricted tissue diffusion and receptor density can dramatically alter drug Listen now to understand how two mechanisms intersect—and why pharmacologists are critical in addressing Why contribute: Join a global, like-minded GPCR community.